Reports Q4 revenue $32M, consensus $30.92M. "Growth in the fourth quarter exceeded our expectations as we saw Tablo’s economic and clinical advantages continue to gain traction with dialysis providers and their patients across our end markets," said Leslie Trigg, Chair and CEO of Outset. "At the same time, we continued to expand gross margins and gain operating leverage, particularly in our sales and field service organizations."
Published first on TheFly
See today’s best-performing stocks on TipRanks >>
Read More on OM:
